Filing Details

Accession Number:
0001179110-14-008044
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-05-09 13:15:46
Reporting Period:
2014-05-07
Filing Date:
2014-05-09
Accepted Time:
2014-05-09 13:15:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1274792 Merrimack Pharmaceuticals Inc MACK Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1108494 E Michael Porter C/O Merrimack Pharmaceuticals, Inc.
One Kendall Square, Suite B7201
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-05-07 5,000 $6.70 495,865 No 4 P Direct
Common Stock Acquisiton 2014-05-08 10,000 $1.71 505,865 No 4 M Direct
Common Stock Acquisiton 2014-05-08 2,500 $2.59 508,365 No 4 M Direct
Common Stock Acquisiton 2014-05-08 2,500 $1.81 510,865 No 4 M Direct
Common Stock Acquisiton 2014-05-08 5,000 $2.12 515,865 No 4 M Direct
Common Stock Acquisiton 2014-05-08 5,000 $6.48 520,865 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-05-08 10,000 $0.00 10,000 $1.71
Common Stock Stock Option (right to buy) Disposition 2014-05-08 2,500 $0.00 2,500 $2.59
Common Stock Stock Option (right to buy) Disposition 2014-05-08 2,500 $0.00 2,500 $1.81
Common Stock Stock Option (right to buy) Disposition 2014-05-08 5,000 $0.00 5,000 $2.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-08-03 No 4 M Direct
0 2017-10-04 No 4 M Direct
0 2018-09-21 No 4 M Direct
0 2019-11-04 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.6999 to $6.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.4699 to $6.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
  3. This option is fully vested.